131875-08-6
中文名称
来沙骨化醇
英文名称
Lexacalcitol
CAS
131875-08-6
分子式
C29 H48 O4
分子量
460.69
MOL 文件
131875-08-6.mol
更新日期
2024/08/24 19:15:45
![131875-08-6 结构式](/CAS/GIF/131875-08-6.gif)
基本信息
中文别名
来沙骨化醇 英文别名
KH 106KH 1060
Lexacalcitol
Lenosacalcitol
Lexacalcideferol
(1S*,3R*,5Z),7aalpha))-(5Z,7E,20R)-20-((4-Ethyl-4-hydroxyhexyl)oxy)-9,10-secopregna-5,7,10(19)-triene-1alpha,3beta-diol
1,3-Cyclohexanediol, 5-[(2E)-2-[(1S,3aS,7aS)-1-[(1R)-1-[(4-ethyl-4-hydroxyhexyl)oxy]ethyl]octahydro-7a-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-, (1R,3S,5Z)-
(1R,3S,5Z)-5-[(2E)-2-[(1S,3aS,7aS)-1-[(1R)-1-(4-ethyl-4-hydroxyhexoxy)ethyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
所属类别
生物化工:激动剂抑制剂物理化学性质
沸点600.3±55.0 °C(Predicted)
密度1.07±0.1 g/cm3(Predicted)
储存条件-20°C, protect from light, stored under nitrogen,unstable in solution, ready to use.
溶解度DMSO
酸度系数(pKa)14.43±0.40(Predicted)
形态粉末
颜色White to off-white
来沙骨化醇价格(试剂级)
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2024/08/19 | HY-32340 | 来沙骨化醇 Lexacalcitol | 131875-08-6 | 1mg | 2560元 |
2024/08/19 | HY-32340 | 来沙骨化醇 Lexacalcitol | 131875-08-6 | 5mg | 6400元 |
2023/10/26 | HY-32340 | 来沙骨化醇 Lexacalcitol | 131875-08-6 | 10mg | 12500元 |
常见问题列表
生物活性
Lexacalcitol (KH1060) 是一种维生素 D 类似物,是细胞生长和免疫反应的有效调节剂。Lexacalcitol 可用于移植排斥反应、银屑病、癌症和自身免疫性疾病的研究。体外研究
Lexacalcitol inhibits cell proliferation by 50% at 10
-12
M (14,000 times more active than la,25(OH)
2
D
3
) in human histiocytic lymphoma cell line U 937.
Lexacalcitol inhibits interleukin-1-induced mouse thymocyte proliferation by 50% at 3×10
-16
M , allogeneic stimulation of mouse spleen lymphocytes at 5×10
-15
M.
体内研究
Lexacalcitol (0.5 mg/kg/2 days; i.p.) in combination with cyclosporin A (CyA) can prevent autoimmune destruction of syngeneic islet grafts in spontaneously diabetic NOD recipients.
Animal Model: | Male and female spontaneously diabetic NOD mice |
Dosage: | 0.5 mg/kg/2 days |
Administration: | Intraperitoneal injection |
Result: | Single treatment with KH1060 or CyA did not result in statistically significant suppression of early graft failure, while the combination of KH1060 and CyA can prevent early graft failure and delay graft rejection of xenogeneic islets in spontaneously diabetic NOD mice. |